Schwab Charles Investment Management Inc. decreased its holdings in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 22.6% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 642,659 shares of the medical research company’s stock after selling 187,433 shares during the period. Schwab Charles Investment Management Inc.’s holdings in EXACT Sciences were worth $38,425,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in EXAS. CIBC World Markets Inc. acquired a new stake in EXACT Sciences during the second quarter valued at approximately $246,000. Trexquant Investment LP acquired a new stake in EXACT Sciences during the second quarter valued at approximately $4,776,000. Greenwood Capital Associates LLC acquired a new stake in EXACT Sciences during the second quarter valued at approximately $445,000. Fluent Financial LLC purchased a new stake in shares of EXACT Sciences in the 2nd quarter valued at approximately $292,000. Finally, Asymmetry Capital Management L.P. lifted its position in shares of EXACT Sciences by 229.2% in the 2nd quarter. Asymmetry Capital Management L.P. now owns 84,937 shares of the medical research company’s stock valued at $5,078,000 after acquiring an additional 59,134 shares in the last quarter. Hedge funds and other institutional investors own 86.35% of the company’s stock.

In other EXACT Sciences news, Director Michael S. Wyzga sold 2,468 shares of the stock in a transaction that occurred on Tuesday, August 28th. The shares were sold at an average price of $74.85, for a total value of $184,729.80. Following the completion of the sale, the director now owns 9,112 shares in the company, valued at approximately $682,033.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Jeffrey Thomas Elliott sold 8,984 shares of the stock in a transaction that occurred on Monday, July 30th. The stock was sold at an average price of $57.78, for a total transaction of $519,095.52. Following the completion of the sale, the chief financial officer now owns 22,690 shares of the company’s stock, valued at approximately $1,311,028.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,014 shares of company stock valued at $1,031,717. Insiders own 3.20% of the company’s stock.

Shares of NASDAQ:EXAS opened at $75.43 on Friday. The company has a debt-to-equity ratio of 0.87, a current ratio of 15.79 and a quick ratio of 15.37. The company has a market capitalization of $9.22 billion, a P/E ratio of -76.19 and a beta of 1.00. EXACT Sciences Co. has a 52 week low of $37.36 and a 52 week high of $76.16.

EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Wednesday, August 1st. The medical research company reported ($0.30) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.03. EXACT Sciences had a negative net margin of 35.24% and a negative return on equity of 20.10%. The business had revenue of $102.89 million during the quarter, compared to the consensus estimate of $104.40 million. During the same quarter in the prior year, the firm earned ($0.27) EPS. The firm’s quarterly revenue was up 78.5% on a year-over-year basis. research analysts expect that EXACT Sciences Co. will post -1.35 earnings per share for the current year.

Several equities research analysts recently commented on the stock. Goldman Sachs Group upped their price target on shares of EXACT Sciences to $75.00 and gave the company a “neutral” rating in a research report on Thursday. BidaskClub upgraded shares of EXACT Sciences from a “hold” rating to a “buy” rating in a research report on Friday. Craig Hallum upped their price target on shares of EXACT Sciences from $54.00 to $74.00 and gave the company a “buy” rating in a research report on Thursday, August 23rd. Zacks Investment Research upgraded shares of EXACT Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, August 21st. Finally, Robert W. Baird upped their price target on shares of EXACT Sciences from $65.00 to $74.00 and gave the company an “outperform” rating in a research report on Thursday, August 23rd. Three analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $75.18.

EXACT Sciences Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Read More: Asset Allocation Models, Which is Right For You?

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).

Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.